Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Aleris in connection with the acquisition of Art Clinic AB
Mandate

Vinge advises Aleris in connection with the acquisition of Art Clinic AB

May 03, 2022 M&A

Vinge advises Aleris Sjukvård AB in connection with the acquisition of Art Clinic AB. Art Clinic AB operates four specialized clinics with five sub-practices in six regions in Sweden.

Aleris is one of Scandinavia’s leading healthcare provider with two million patient appointments per year and operates specialized care at over 130 locations in Sweden, Norway and Denmark. Aleris strengthens through the transaction its specialized healthcare within orthopedics, back surgery as well as aesthetic and reconstructive plastic surgery in Sweden.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted of Christina Kokko, Samra Baytar, Olivia Belding and Elias Bohlin (M&A), Johan Wahlbom (Competition), Christoffer Nordin, Sam Fakhraie Ardekani and Max Hetta (Agreements), Emil Lindwall (Employment), Nour Makie (Banking and Finance), Karolina Fuhrman (IT/GDPR), Frida Ställborn (Real Estate) and Jessica Henning (VDR specialist).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024